BriaCell Therapeutics Cor... (BCTX)
BriaCell Therapeutics Statistics
Share Statistics
BriaCell Therapeutics has 5.72M shares outstanding. The number of shares has increased by 202.79% in one year.
| Shares Outstanding | 5.72M |
| Shares Change (YoY) | 202.79% |
| Shares Change (QoQ) | 25.25% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 452 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 206.89K, so 5.58% of the outstanding shares have been sold short.
| Short Interest | 206.89K |
| Short % of Shares Out | 5.58% |
| Short % of Float | 5.8% |
| Short Ratio (days to cover) | 2.6 |
Valuation Ratios
The PE ratio is -39.39 and the forward PE ratio is -2.11. BriaCell Therapeutics's PEG ratio is 0.47.
| PE Ratio | -39.39 |
| Forward PE | -2.11 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -77.98 |
| P/FCF Ratio | -7.56 |
| PEG Ratio | 0.47 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BriaCell Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.49, with a Debt / Equity ratio of 0.
| Current Ratio | 0.49 |
| Quick Ratio | 0.49 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-294,776.88 |
| Employee Count | 16 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -87.8% in the last 52 weeks. The beta is 1.71, so BriaCell Therapeutics's price volatility has been higher than the market average.
| Beta | 1.71 |
| 52-Week Price Change | -87.8% |
| 50-Day Moving Average | 4.12 |
| 200-Day Moving Average | 8.6 |
| Relative Strength Index (RSI) | 45.74 |
| Average Volume (20 Days) | 1,504,627 |
Income Statement
| Revenue | n/a |
| Gross Profit | -82.58K |
| Operating Income | -32.81M |
| Net Income | -4.72M |
| EBITDA | -4.77M |
| EBIT | -4.85M |
| Earnings Per Share (EPS) | -0.29 |
Balance Sheet
The company has 862.09K in cash and 0 in debt, giving a net cash position of 862.09K.
| Cash & Cash Equivalents | 862.09K |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -85.48M |
| Total Assets | 9.36M |
| Working Capital | 1.93M |
Cash Flow
In the last 12 months, operating cash flow was -24.13M and capital expenditures -456.8K, giving a free cash flow of -24.58M.
| Operating Cash Flow | -24.13M |
| Capital Expenditures | -456.8K |
| Free Cash Flow | -24.58M |
| FCF Per Share | -1.49 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BCTX is $32, which is 680.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $32 |
| Price Target Difference | 680.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jan 29, 2025. It was a backward split with a ratio of 1:15.
| Last Split Date | Jan 29, 2025 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -23.38 |
| Piotroski F-Score | 1 |